Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios
ACCESSWIRE
This Definitive Agreement is expected to generate an excess of $
47,5M CAD
), a leader in cannabinoid-derived drug discovery and development announced today the signing of a Definitive Agreement with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo™ Adversa®, QIXLEEF™ and ENJOUCA™ in Denmark, Norway, Sweden, Finland, and Germany.
Subject to registration with the European Medicines Agency (EMA), DanCann Pharma will handle the exclusive sales and distribution in the Nordics and Germany for Reduvo™ Adversa® and QIXLEEF™, a botanical cannabinoid-derived medicine, as well as Tetra s medicinal cannabis product ENJOUCA™.